Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
BOSTON - Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotech firm with a market capitalization of $374 million, will present additional Phase 1 data on bel-sar (AU-011) for non-muscle invasive bladder cancer (NMIBC) treatment at the 40th Annual European Association of Urology (EAU) Congress in Madrid, Spain, from March 21-24, 2025. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet, positioning it well for continued clinical development. The company will also participate in the EAU Research Forum during the congress.
The new data stems from a study evaluating the safety and efficacy of bel-sar, a Virus-like-Drug-Conjugate (VDC), in patients with NMIBC. The presentation, led by Dr. Seth Lerner from Baylor College of Medicine, is scheduled for Saturday, during the congress. Additionally, a discussion titled "Virus-like Drug Conjugates (VDC), a paradigm shifting approach for the treatment of bladder cancer: Mechanism, First Insights, and Future Directions" will take place on Sunday, featuring a panel of urology experts.
Following the EAU Congress, Aura will host a virtual urologic oncology investor event on Monday at 4:30 pm Eastern Time. The event will feature key opinion leaders in the field, including Dr. Neal Shore, Dr. Gary Steinberg, and Dr. Jennifer A. Linehan, who will discuss the ongoing Phase 1 trial in NMIBC. With analyst price targets ranging from $20 to $23, significantly above the current trading price of $7.49, market experts see substantial upside potential. InvestingPro subscribers can access additional insights and financial metrics to better evaluate this opportunity. The trial is a multi-center, open-label clinical study designed to assess the safety and feasibility of local administration of bel-sar as a monotherapy prior to transurethral resection of bladder tumor (TURBT), the standard of care procedure.
The investor event aims to provide updates on the bladder cancer program, including the planned expansion of the Phase 1b/2 trial and future development plans. A live Q&A session will follow the discussions. The presentations and investor event will be accessible via webcast on the Aura Biosciences website.
Aura Biosciences focuses on developing precision therapies for solid tumors to preserve organ function. Its lead candidate, bel-sar, is in late-stage development for primary choroidal melanoma and early-stage development for other ocular oncology indications and bladder cancer. The company maintains a healthy current ratio of 12.47 and received a FAIR overall financial health score from InvestingPro. Investors should note the upcoming earnings report on March 12, 2025, which could serve as a significant catalyst for the stock.
This news article is based on a press release statement from Aura Biosciences. The forward-looking statements in the press release are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.